EP3365021A4 - Hilfsstoffverbindungen für biopolymerformulierungen - Google Patents
Hilfsstoffverbindungen für biopolymerformulierungen Download PDFInfo
- Publication number
- EP3365021A4 EP3365021A4 EP16858314.4A EP16858314A EP3365021A4 EP 3365021 A4 EP3365021 A4 EP 3365021A4 EP 16858314 A EP16858314 A EP 16858314A EP 3365021 A4 EP3365021 A4 EP 3365021A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- excipient compounds
- biopolymer formulations
- biopolymer
- formulations
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001222 biopolymer Polymers 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23205025.2A EP4324482A2 (de) | 2015-10-23 | 2016-10-21 | Hilfsstoffverbindungen für biopolymerformulierungen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245513P | 2015-10-23 | 2015-10-23 | |
PCT/US2016/058169 WO2017070501A1 (en) | 2015-10-23 | 2016-10-21 | Excipient compounds for biopolymer formulations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23205025.2A Division EP4324482A2 (de) | 2015-10-23 | 2016-10-21 | Hilfsstoffverbindungen für biopolymerformulierungen |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3365021A1 EP3365021A1 (de) | 2018-08-29 |
EP3365021A4 true EP3365021A4 (de) | 2019-06-05 |
Family
ID=58558088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16858314.4A Pending EP3365021A4 (de) | 2015-10-23 | 2016-10-21 | Hilfsstoffverbindungen für biopolymerformulierungen |
EP23205025.2A Withdrawn EP4324482A2 (de) | 2015-10-23 | 2016-10-21 | Hilfsstoffverbindungen für biopolymerformulierungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23205025.2A Withdrawn EP4324482A2 (de) | 2015-10-23 | 2016-10-21 | Hilfsstoffverbindungen für biopolymerformulierungen |
Country Status (3)
Country | Link |
---|---|
EP (2) | EP3365021A4 (de) |
CA (2) | CA3002373A1 (de) |
WO (1) | WO2017070501A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
EP3624846B1 (de) * | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | Hochkonzentrierte proteinformulierungen mit reduzierter viskosität beinhaltend eine mischung von nicotinicsäure and tryoptophan |
EP3886909A4 (de) * | 2018-11-29 | 2023-03-29 | Comera Life Sciences, Inc. | Hilfsstoffverbindungen zur proteinverarbeitung |
KR20220122993A (ko) * | 2019-11-26 | 2022-09-05 | 코메라 라이프 사이언시스, 인코포레이티드 | 바이오폴리머 제형을 위한 부형제 화합물 |
AU2021308997A1 (en) | 2020-07-13 | 2023-02-02 | Merck Patent Gmbh | Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027750A1 (en) * | 1996-02-01 | 1997-08-07 | Anthea Enterprises Incorporated | Aqueous caffeine dosage forms |
WO2004037018A1 (en) * | 2002-10-23 | 2004-05-06 | Quercegen Holdings Llc | Composition for enhancing physical performance |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2230965A (en) | 1940-06-14 | 1941-02-04 | American Cyanamid Co | Process of preparing guanyl taurine |
WO2009065126A2 (en) * | 2007-11-16 | 2009-05-22 | Boston Protein Solutions | Excipients for protein stabilization |
CA2707483A1 (en) * | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
EP3808338A1 (de) | 2013-09-11 | 2021-04-21 | Eagle Biologics, Inc. | Flüssige proteinformulierungen mit ionischen flüssigkeiten |
US20160074515A1 (en) * | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
-
2016
- 2016-10-21 EP EP16858314.4A patent/EP3365021A4/de active Pending
- 2016-10-21 WO PCT/US2016/058169 patent/WO2017070501A1/en active Application Filing
- 2016-10-21 CA CA3002373A patent/CA3002373A1/en not_active Abandoned
- 2016-10-21 EP EP23205025.2A patent/EP4324482A2/de not_active Withdrawn
- 2016-10-21 CA CA3129181A patent/CA3129181C/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027750A1 (en) * | 1996-02-01 | 1997-08-07 | Anthea Enterprises Incorporated | Aqueous caffeine dosage forms |
WO2004037018A1 (en) * | 2002-10-23 | 2004-05-06 | Quercegen Holdings Llc | Composition for enhancing physical performance |
Also Published As
Publication number | Publication date |
---|---|
EP3365021A1 (de) | 2018-08-29 |
CA3129181C (en) | 2023-10-31 |
CA3129181A1 (en) | 2017-04-27 |
CA3002373A1 (en) | 2017-04-27 |
EP4324482A2 (de) | 2024-02-21 |
WO2017070501A1 (en) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3302426A4 (de) | D2o-stabilisierte pharmazeutische formulierungen | |
EP3160484A4 (de) | Viskositätsreduzierende hilfsstoffverbindungen für proteinformulierungen | |
EP3322441A4 (de) | Impfstoffzusammensetzungen | |
EP3319606A4 (de) | Pharmazeutische verbindung | |
EP3102190A4 (de) | Neuartige pharmazeutische formulierungen | |
EP3129028A4 (de) | Pharmazeutische zusammensetzungen | |
EP3104860A4 (de) | Pharmazeutische verbindungen | |
EP3253382A4 (de) | Pharmazeutische zusammensetzungen für eine kombinationstherapie | |
EP3280421A4 (de) | Pharmazeutische zusammensetzungen für eine kombinationstherapie | |
EP3193888A4 (de) | Neuartige formulierungen | |
EP3365021A4 (de) | Hilfsstoffverbindungen für biopolymerformulierungen | |
EP3541385A4 (de) | Pharmazeutische formulierungen | |
EP3310439A4 (de) | Pharmazeutische zusammensetzungen für anästhesiologische anwendungen | |
EP3160491A4 (de) | Pharmazeutische zusammensetzungen | |
EP3362052A4 (de) | Verfahren zur herstellung von formulierungen für gastrointestinale therapien | |
EP3349750A4 (de) | Pharmazeutische verbindung | |
EP3102564A4 (de) | Tablettenformulierung für cgrp-aktive verbindungen | |
EP3141243A4 (de) | Pharmazeutische zusammensetzung | |
EP3389633A4 (de) | Pharmazeutische zusammensetzungen mit einem phenylaminopyrimidinderivat | |
EP3344293A4 (de) | Vlp-stabilisierte impfstoffzusammensetzungen | |
AU2016218074B2 (en) | Pharmaceutical formulation | |
EP3524250A4 (de) | Pharmazeutische zusammensetzung | |
EP3373928A4 (de) | Neuartige formulierungen | |
EP3383371A4 (de) | Pharmazeutische formulierung | |
EP3337463A4 (de) | Pharmazeutische formulierungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180419 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: REFORM BIOLOGICS, LLC |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190508 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/12 20060101ALI20190502BHEP Ipc: A61K 47/22 20060101AFI20190502BHEP Ipc: A61K 47/18 20170101ALI20190502BHEP Ipc: A61K 38/00 20060101ALI20190502BHEP Ipc: A61K 47/06 20060101ALI20190502BHEP Ipc: A61K 39/395 20060101ALI20190502BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210115 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: REFORM BIOLOGICS, INC. |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: COMERA LIFE SCIENCES, INC. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230508 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230516 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240104 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |